A large pharmaceutical company is spending more than $11 billion to acquire the maker of two drugs used to treat skin cancer.
New York-based Pfizer said Monday it would acquire Boulder, Colorado-based Array BioPharma for $11.4 billion, or $48 per share.
{iframe}https://medcitynews.com/2019/06/pfizer-to-buy-array-biopharma-for-11-4b/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=73783870&_hsenc=p2ANqtz-_FAdHY5P3wUFEFYG5gpfo0P_CMeAILiQH5gHCcAa0va41YaROiYY_40UD53-dLKidFEpPqprqrTa9havLCQGSVr_xUAQ&_hsmi=73783870{/iframe}